Literature DB >> 8284688

European studies of interleukin-2 in metastatic renal cell carcinoma.

J Atzpodien1, H Kirchner, E L Hänninen, A Körfer, M Fenner, T Menzel, M Deckert, A Franzke, U Jonas, H Poliwoda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8284688

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  6 in total

1.  Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.

Authors:  Olaf Anselm Brinkmann; Frank Bruns; Georg Gosheger; Oliver Micke; Lothar Hertle
Journal:  World J Urol       Date:  2005-04-19       Impact factor: 4.226

2.  A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect.

Authors:  Andrea Nicolini; Massimo Conte; Giuseppe Rossi; Paola Ferrari; Angelo Carpi; Paolo Miccoli
Journal:  Tumour Biol       Date:  2010-06-30

3.  Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.

Authors:  J Atzpodien; H Kirchner; S Duensing; E Lopez Hänninen; A Franzke; J Buer; M Probst; P Anton; H Poliwoda
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

Authors:  C M van Herpen; R L Jansen; W H Kruit; K Hoekman; G Groenewegen; S Osanto; P H De Mulder
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 5.  The role of adjuvant immunotherapy in renal cell carcinoma.

Authors:  Peter F A Mulders; Pieter H M De Mulder
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

6.  Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.

Authors:  A Ravaud; N Trufflandier; J M Ferrière; M Debled; J Palussière; L Cany; R Gaston; S Mathoulin-Pélissier; B N Bui
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.